The blood disease specialist secured a boost from Alexandria Real Estate Equities, Novo and Access Biotechnology to move two assets into phase 2 trials.

Disc Medicine, a US-based developer of treatments for haematologic diseases, brought in $90m in a series B round yesterday featuring Alexandria Venture Investments, the venture capital arm of life sciences real estate trust Alexandria Real Estate Equities.

Pharmaceutical firm Novo and diversified conglomerate Access Industries’ biotech arm Access Biotechnology also took part in the round, which was led by OrbiMed.

Arix BioScience, 5AM Ventures, Janus Henderson Investors, Rock Springs Capital, Nanthala Capital Management, Willett Advisors and Atlas Venture filled out…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn